BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 12024032)

  • 1. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.
    Slupianek A; Hoser G; Majsterek I; Bronisz A; Malecki M; Blasiak J; Fishel R; Skorski T
    Mol Cell Biol; 2002 Jun; 22(12):4189-201. PubMed ID: 12024032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion oncogenic tyrosine kinases alter DNA damage and repair after genotoxic treatment: role in drug resistance?
    Hoser G; Majsterek I; Romana DL; Slupianek A; Blasiak J; Skorski T
    Leuk Res; 2003 Mar; 27(3):267-73. PubMed ID: 12537980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.
    Rink L; Slupianek A; Stoklosa T; Nieborowska-Skorska M; Urbanska K; Seferynska I; Reiss K; Skorski T
    Blood; 2007 Jul; 110(2):651-60. PubMed ID: 17431132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR/ABL stimulates WRN to promote survival and genomic instability.
    Slupianek A; Poplawski T; Jozwiakowski SK; Cramer K; Pytel D; Stoczynska E; Nowicki MO; Blasiak J; Skorski T
    Cancer Res; 2011 Feb; 71(3):842-51. PubMed ID: 21123451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells.
    Turner SD; Alexander DR
    Leukemia; 2006 Apr; 20(4):572-82. PubMed ID: 16482213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin.
    Majsterek I; Slupianek A; Blasiak J
    Anticancer Drugs; 2003 Sep; 14(8):625-31. PubMed ID: 14501384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance.
    Slupianek A; Schmutte C; Tombline G; Nieborowska-Skorska M; Hoser G; Nowicki MO; Pierce AJ; Fishel R; Skorski T
    Mol Cell; 2001 Oct; 8(4):795-806. PubMed ID: 11684015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
    Cramer K; Nieborowska-Skorska M; Koptyra M; Slupianek A; Penserga ET; Eaves CJ; Aulitzky W; Skorski T
    Cancer Res; 2008 Sep; 68(17):6884-8. PubMed ID: 18757400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.
    Heath C; Cross NC
    J Biol Chem; 2004 Feb; 279(8):6666-73. PubMed ID: 14660670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
    Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
    Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
    Horita M; Andreu EJ; Benito A; Arbona C; Sanz C; Benet I; Prosper F; Fernandez-Luna JL
    J Exp Med; 2000 Mar; 191(6):977-84. PubMed ID: 10727459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?
    Majsterek I; Slupianek A; Hoser G; Skórski T; Blasiak J
    Biochimie; 2004 Jan; 86(1):53-65. PubMed ID: 14987801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
    Lacronique V; Boureux A; Monni R; Dumon S; Mauchauffé M; Mayeux P; Gouilleux F; Berger R; Gisselbrecht S; Ghysdael J; Bernard OA
    Blood; 2000 Mar; 95(6):2076-83. PubMed ID: 10706877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase p85{alpha} subunit-dependent interaction with BCR/ABL-related fusion tyrosine kinases: molecular mechanisms and biological consequences.
    Ren SY; Bolton E; Mohi MG; Morrione A; Neel BG; Skorski T
    Mol Cell Biol; 2005 Sep; 25(18):8001-8. PubMed ID: 16135792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcr/Abl activates transcription of the Bcl-X gene through STAT5.
    Gesbert F; Griffin JD
    Blood; 2000 Sep; 96(6):2269-76. PubMed ID: 10979976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
    Carlesso N; Frank DA; Griffin JD
    J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells.
    de Groot RP; Raaijmakers JA; Lammers JW; Koenderman L
    Mol Cell Biol Res Commun; 2000 May; 3(5):299-305. PubMed ID: 10964754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine.
    Gloc E; Warszawski M; Młynarski W; Stolarska M; Hoser G; Skorski T; Błasiak J
    Acta Biochim Pol; 2002; 49(1):121-8. PubMed ID: 12136932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
    Hoover RR; Gerlach MJ; Koh EY; Daley GQ
    Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.